Adrenocortical carcinoma

ISSN: 00177768
1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Adrenocortical carcinoma ACC) is a rare cancer with a generally poor prognosis. In approximately 60% of cases the initial clinical manifestations are due to hypersecretion of adrenocortical hormones. Cushing's syndrome is the most frequent hormonal manifestation. In the remainder of the cases the tumor is identified after imaging procedures for non-specific complaints such as abdominal pain and nausea. Medical therapy is employed in patients with unresectable or partially resected tumor and metastatic disease. The current accepted treatment is a combination of Mitotane with chemotherapy, aimed at controlling hormonal hypersecretion and reduction of tumor mass. In ACC patients there is wide variability in the course of the disease: some with metastatic disease will survive for more than 10 years, others succumb to the disease within months.

References Powered by Scopus

The clinically inapparent adrenal mass: Update in diagnosis and management

655Citations
N/AReaders
Get full text

Clinical review: Adrenocortical carcinoma: Clinical update

638Citations
N/AReaders
Get full text

Adjuvant mitotane treatment for adrenocortical carcinoma

630Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Resorcylic acid lactone L-783,277 inhibits the growth of the human adrenal cancer cell line H295r in vitro

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gur, C., Salmon, A., Silvetski, N., & Gross, D. J. (2008, June). Adrenocortical carcinoma. Harefuah.

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

86%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Save time finding and organizing research with Mendeley

Sign up for free